Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068068 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
A Phase 2 study, sponsored by Light Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00068068 is a Phase 2 study that has completed, run by Light Sciences. The registered enrollment target is 25 participants.
The verdict
NCT00068068, a Phase 2 study, has completed, sponsored by Light Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer. Litx is a next-generation photodynamic therapy platform in which the drug, talaporfin sodium (LS11), is activated by light from the light-emitting diode (LED)-based light infusion device, inserted directly into the tumor through the skin prior to treatment.
Interventions
- PROCEDURE Phototherapy
- PROCEDURE Photodynamic therapy
- DRUG Talaporfin sodium (LS11)
- DEVICE LED-based light infusion device
- DEVICE Light emitting diodes (LED)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068068
The ClinicalTrials.gov registry entry for NCT00068068 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Light Sciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Phototherapy is the first listed.
NCT00068068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068068 about?
NCT00068068 is a clinical study titled "Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases". The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer. Litx is a next-generation photodynamic therapy platform in which the drug, talaporfin sodium (LS11), is activated by light from the light-emi...
What is the current status of trial NCT00068068?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2003-10.
What interventions are being tested in trial NCT00068068?
The interventions under investigation include: Phototherapy (PROCEDURE), Photodynamic therapy (PROCEDURE), Talaporfin sodium (LS11) (DRUG), LED-based light infusion device (DEVICE), Light emitting diodes (LED) (DEVICE).
Who is sponsoring clinical trial NCT00068068?
This trial is sponsored by Light Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.